- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04948788
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
September 22, 2021 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Phase I/ II Study of SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma in Adults
The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
102
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weiwei Wang
- Phone Number: 021-61053363
- Email: weiwei.wang@hengrui.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of B-cell NHL such as DLBCL, FL and MCL
- Patients received at least 2 lines of systemic therapy
- Previously received anti- CD20 treatment
- Patients in stage II should also be unsuitable or unwilling to receive allogeneic hematopoietic stem cell transplantation
- Patients must have an acceptable organ function
Exclusion Criteria:
- Previously treated with PI3K inhibitors or BTK inhibitors
- Unresolved toxicity of CTCAE grade > 1 from prior anti-lymphoma therapy
- Chemotherapy or other investigational therapy within 28 days (or 5 times the half-life time, whichever is shorter) before starting cycle 1
- Significant concurrent medical disease or condition which according to the investigators' judgement
- Active hepatitis B, C or HIV infection
- Infection requiring treatment 2 weeks prior to the first dosing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SHR1459 + YY-20394 (Stage 1)
|
SHR1459 plus YY-20394
|
EXPERIMENTAL: SHR1459 + YY-20394 (Stage 2)
|
SHR1459 plus YY-20394
|
EXPERIMENTAL: GemOx (Stage 2)
|
Gemcitabine-Oxaliplatin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Stage 1: MTD (Maximum tolerated dose)or RP2D(Recommended Phase II Dose) of SHR1459 and YY-20394;
Time Frame: Minimum observation period is 28 days for the maximum dose cohort
|
Minimum observation period is 28 days for the maximum dose cohort
|
Stage 2: Overall response rate (ORR)
Time Frame: 8 weeks after last patient first visit (LPFV)
|
8 weeks after last patient first visit (LPFV)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse Events
Time Frame: At every treatment and follow up visit until disease progression. Expected to be for up to 6 months
|
At every treatment and follow up visit until disease progression. Expected to be for up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
October 1, 2021
Primary Completion (ANTICIPATED)
April 1, 2023
Study Completion (ANTICIPATED)
October 1, 2023
Study Registration Dates
First Submitted
June 28, 2021
First Submitted That Met QC Criteria
July 1, 2021
First Posted (ACTUAL)
July 2, 2021
Study Record Updates
Last Update Posted (ACTUAL)
September 28, 2021
Last Update Submitted That Met QC Criteria
September 22, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Lymphoma
- Lymphoma, B-Cell
- Recurrence
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Oxaliplatin
Other Study ID Numbers
- SHR1459-II-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
-
Miltenyi Biomedicine GmbHActive, not recruitingNon-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma RecurrentGermany
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterNot yet recruitingHIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)RecruitingRecurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin LymphomaUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma and other conditionsUnited States
Clinical Trials on SHR1459 ;YY-20394
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownMantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownRelapsed or Refractory Peripheral T-Cell LymphomaChina
-
Shanghai YingLi Pharmaceutical Co. Ltd.Not yet recruiting
-
Shanghai YingLi Pharmaceutical Co. Ltd.Not yet recruitingIndolent B-cell Lymphoma
-
Ruijin HospitalTianjin Medical University Cancer Institute and HospitalNot yet recruitingFocus on the Lymphoma Including B/T-cell LymphomaChina
-
Shanghai YingLi Pharmaceutical Co. Ltd.Not yet recruitingEffectiveness,Safety,Thymic Cancer
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownLymphoma, FollicularChina
-
Shanghai YingLi Pharmaceutical Co. Ltd.RecruitingPeripheral T/NK Cell Lymphoma (R/R PTCL)United States
-
Shanghai YingLi Pharmaceutical Co. Ltd.Unknown
-
Shanghai YingLi Pharmaceutical Co. Ltd.Unknown